DGAP-News: PharmaSGP Group completes acquisition of OTC brand portfolio (Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R)) from GSK

PharmaSGP Group completes acquisition of OTC brand portfolio (Baldriparan^(R), Formigran^(R), Spalt^(R) and Kamol^(R)) from GSK

Gräfelfing, August 31, 2021 - PharmaSGP Holding SE announces the formal completion of the purchase agreement signed mid of June with GlaxoSmithKline Group on the acquisition of an OTC portfolio comprising the brands Baldriparan^(R), Formigran^(R), Spalt^(R) and Kamol^(R).

The completion of the purchase strategically strengthens PharmaSGP's operations by further expanding the category "Health Brands", enlarging the scope of indications and tapping new markets. Natalie Weigand, CEO of PharmaSGP, was very satisfied with the transaction: "The acquisition and integration of established brands with potential for value growth is a key component of our growth strategy. Baldriparan^(R) has been established on the market for 67 years and is the leading OTC brand for natural valerian sleeping aids sold in pharmacies in Germany. We are thus opening up the new indication of sleep disorders. Additionally, Formigran^(R), Spalt^(R) and Kamol^(R) strengthen our strategically important category 'pain therapy'". These four iconic brands with a long tradition in their target markets enjoy a high level of trust and loyalty with consumers, physicians and pharmacists. In 2020, the products of the brand portfolio were distributed in eight countries. Thus, the Group will also be active in Switzerland, Hungary, Poland, Czech Republic and Slovakia in future.

Michael Rudolf, CFO of PharmaSGP, considers the transaction as an achievement of a further milestone on the growth path: "With our products in the field of sleeping disorders and pain therapy, we address two of the best-selling and further growing indications in pharmacies. Thanks to our pan-European platform, we will be able to leverage potential for value enhancement. This is going to positively impact the business development in the year 2021 and beyond. We are convinced of this!"

In September, PharmaSGP will publish a consolidated revenues and earnings forecast for the financial year 2021, including the effects of Baldriparan^(R), Formigran^(R), Spalt^(R) and Kamol^(R).

CONTACT

cometis AG
Claudius Krause
Phone: +49-611-20585528
Email: [email protected]

ABOUT PHARMASGP HOLDING SE

PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with the focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.

The Company's core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX^(R) for rheumatic pain and Restaxil^(R) for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio is expanded by the brands Baldriparan^(R), Formigran^(R), Spalt^(R) and Kamol^(R), thus also strengthening or developing the indications pain and sleep disorder.

In 2020, PharmaSGP generated revenues of EUR 63.2 million at an adjusted EBIT margin of 26.1 %.

In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP's product offering, increase PharmaSGP's European footprint, and accelerate its growth strategy especially by capitalizing on selected M&A opportunities.